Eli Lilly's obesity lead is only the starting point. See what its pipeline, manufacturing build-out, pricing pressure, and earnings trajectory could mean for the stock's next chapter.
Stansberry Research's Whitney Tilson argues record highs mask a bifurcated market, favoring Joby Aviation, Casey's General Stores, and Eli Lilly as value picks outside the AI trade.
Eli Lilly's revenue surged 44.7% in 2025, but Novo Nordisk trades at less than a quarter of its valuation multiple, a stark contrast that reshapes the risk-reward calculus.
U.S. healthcare stocks delivered 28.8% gains over one year versus 22.5% for international peers. Both funds carry nearly identical expense ratios and low volatility profiles.
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a committed dividend through its transformation.
Fidelity offers lower costs and steadier returns, while State Street targets smaller biotech companies with higher volatility and recent outperformance.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...
